BIO Asia–Taiwan’s Post

DGP Research Award 2024: Recognizing DZL Scientists' Study on Pulmonary Fibrosis! Congratulations to Janine Gote-Schniering and Niklas Lang from the Helmholtz Munich Institute of Lung Health and Immunity for winning the #Pneumology Research Prize 2024! Their innovative work on pulmonary fibrosis using the Precision-Cut Lung Slice (#PCLS) model has been recognized as the best basic scientific research by the German Respiratory Society (Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V., #DGP). Using the advanced hPCLS model, they successfully simulated fibrotic processes in healthy human #lung tissue and analyzed these mechanisms at the single-cell level with state-of-the-art #genomics and #AI-assisted analyses. This model provides a more accurate depiction of the lung's complexity, enabling the study of cellular changes in the early stages of pulmonary fibrosis and testing new antifibrotic medications directly in human tissue. This significant research holds promise for developing new therapies for pulmonary fibrosis, a disease currently lacking effective treatment options. The prize, awarded at the DGP Annual Congress in Mannheim, includes a €10,000 endowment. Read more on the DZL website by following the link below: https://lnkd.in/ew2kAuH7 #DZL #DZG #PulmonaryResearch #LungDisease #Science #PulmonaryFibrosis #MedicalResearch #DGPResearchAward #PrecisionCutLungSlice #HelmholtzZentrumMünchen #LungHealth #Innovation #AI #SingleCellGenomics #DZL

💥 MSC-EXOs for Ocular Diseases: Is Heterogeneity a Strength or Weakness? A recent paper explores the potential of mesenchymal stem cell-derived exosomes (MSC-EXOs) as a treatment for retinal diseases such as AMD and RP. Heterogeneity refers to the variation in size, cargo, and function between different MSC-EXO populations. This variability arises from factors like the source of the MSCs, their culture conditions, and the methods used to isolate the exosomes. The question that arises is whether this heterogeneity is a roadblock or a potential advantage in developing new therapies. 🔍Potential Benefits: - Broader Therapeutic Reach: A diverse mix of exosomes could target various aspects of a complex disease. - Adaptability to Individual Needs: Heterogeneity might allow for personalized medicine approaches, tailoring the exosome mixture to the specific needs of each patient. ⛰Challenges: - Inconsistent Effects: Exosome batches can vary, making it hard to get the same results each time and determine the right dose. - Limited Source Material: Sourcing enough MSCs to produce clinically relevant quantities of exosomes. - Scalable Purification: Developing efficient and cost-effective methods for isolating pure exosome populations in large quantities. From personal experience, I know that scalable purification of exosomes remains a major hurdle for therapy development. However, once these issues are solved, I believe exosomes could well be a game changer in medicine. What are your thoughts on this exciting research area?💡 Read the full article here: 🔗 https://lnkd.in/ehJUwRMY

Exciting Medical Breakthrough! Researchers have discovered a promising way to significantly reduce chemotherapy-induced peripheral neuropathy (CIPN) by 50 to 70 percent through neuromuscular training. CIPN is a distressing side effect of chemotherapy, often causing chronic pain, numbness, and balance issues, which can interrupt treatment and impact quality of life. Unlike other side effects, CIPN lacks direct pharmacological treatments, making effective management critical. In a groundbreaking study published in JAMA Internal Medicine, scientists from the University of Basel and the German Sport University Cologne conducted a randomized trial involving 158 cancer patients undergoing therapies like oxaliplatin or vinca alkaloids. These therapies commonly lead to CIPN in up to 90 percent of patients, with significant chronic effects in nearly half of them. Participants were divided into three groups: sensorimotor training (SMT) focusing on balance challenges, whole-body vibration (WBV) training on a vibrating platform, and standard treatment as usual (TAU). Lead author Fiona Streckmann and her team found that both SMT and WBV significantly reduced the occurrence and severity of CIPN compared to TAU, offering a promising avenue for managing this debilitating condition. The benefits extend beyond symptom reduction, potentially improving patients' resilience and adaptability to chemotherapy. This breakthrough underscores the potential of non-pharmacological interventions in enhancing cancer care outcomes and improving survival rates. It's a hopeful step forward in the fight against cancer-related neuropathies, offering patients new possibilities for managing treatment side effects effectively. Mediworld Middle East #CIPN #who #ChemotherapySideEffects #NeuromuscularTraining #MedicalResearch #JAMAInternalMedicine #CancerTreatment #MedicalBreakthrough #PeripheralNeuropathy #ChemotherapyEffects #CancerResearch #MedicalScience #NeurologicalHealth #Oncology #SurvivalRates #PatientCare #HealthcareInnovation #ClinicalTrials #UniversityResearch

Exciting news in Alzheimer's research 🎉🎉 The FDA has granted Breakthrough Device Designation to a new blood test, the Elecsys pTau217, developed by Roche in collaboration with Eli Lilly. This innovative test measures phosphorylated tau-217 (pTau217), a biomarker linked to Alzheimer's disease, and offers a less invasive, more accessible alternative to traditional diagnostic methods like cerebrospinal fluid tests and PET scans. Quanterix's Simoa pTau217 test, another significant development, also received the same designation. This test can predict Alzheimer's in people with cognitive decline, potentially allowing for earlier intervention. These advancements hold promise for improving early diagnosis and treatment strategies, which could significantly impact patient outcomes. For more details, check out the full articles: - [Roche Diagnostics](https://lnkd.in/gYPViq-7) - [Alzheimer's News Today](https://lnkd.in/gzyzYvUv) - [Washington University School of Medicine](https://lnkd.in/ggUZ6hj5)

🚨 New Insights into Vascular Inflammation: VAP-1's Role in Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) 🚨 Exciting developments have emerged from a recent study published in Frontiers in Medicine, focusing on Vascular-adhesion protein 1 (VAP-1). This protein plays a critical role in the immune response by facilitating leukocyte migration and contributing to vascular inflammation. 🔬 Key Highlights: VAP-1 is predominantly expressed in vascular smooth muscle and endothelial cells. Under inflammatory conditions, it relocates to the endothelial cell surface, enabling immune cell adhesion and migration. The study explores VAP-1's involvement in GCA and PMR, linking its enzymatic activity to oxidative stress and tissue damage. Advanced imaging techniques like [68Ga]Ga-DOTA-Siglec-9 PET/CT have been pivotal in visualizing VAP-1's role in these conditions, providing new avenues for diagnosis and treatment. 🧬 Implications: Understanding the multifaceted role of VAP-1 could pave the way for more targeted therapies in managing vascular inflammatory disorders, potentially improving outcomes for patients with GCA and PMR. 📈 Check out Figure 1 below, which illustrates the translocation of VAP-1 during inflammatory responses, leading to enhanced leukocyte adhesion and migration. 👉 Read the full article for a deeper dive into this groundbreaking research: https://lnkd.in/eB9sB8ss #VascularHealth #Immunology #Rheumatology #GCA #PMR #MedicalResearch #UKB Universitätsklinikum Bonn Rheinische Friedrich-Wilhelms-Universität Bonn Dr. med. Simon M. Petzinna Claus-Jürgen Bauer

🎊 Exciting News! 🎊 We are thrilled to announce that our latest research paper, "The Association between Trimethylamine N-oxide Levels and Coronary Microvascular Dysfunction and Prognosis in Patients with ST-Elevation Myocardial Infarction," has been published in #Atherosclerosis. In this study, we explored the potential of Trimethylamine N-oxide (TMAO), a gut microbiota biomarker for diagnosing coronary microvascular dysfunction (CMD), and its impact on clinical outcomes. The findings could improve the clinical stratification and diagnostic plan in treating STEMI patients. Special thanks to the leading author, Dr.Ali A., the amazing team at the CORRIB Research Centre for Advanced Imaging and Core Laboratory, and to our mentors, Prof. Patrick W. Serruys and Prof. Yoshinobu Onuma, for their invaluable guidance. Check out the full paper here: https://shorturl.at/HiFtR #Cardiology #Research #STEMI #CoronaryMicrovascularDysfunction #TMAO #ESC2024 #Atherosclerosis

The article discusses Mayo Clinic's new "omics" strategy, which aims to integrate precision medicine into everyday clinical practice. The strategy is centered around four interconnected pillars: Rare Disease Omics, Population Omics, Functional Omics, and Digital Omics. These pillars leverage advanced technologies like AI and multi-omics analysis to enhance disease diagnosis, prognosis, and treatment. The Rare Disease Omics pillar focuses on improving clinical diagnoses for rare diseases, the Population Omics pillar aims to make genomic testing more accessible and integrate polygenic risk scores into clinical screenings, the Functional Omics pillar develops novel models to speed up scientific discovery, and the Digital Omics pillar works on making genomic data more accessible and actionable for healthcare providers. Overall, this new omics strategy represents a significant advancement in the field of individualized medicine. #MayoClinic #omics #precisionmedicine #healthcare #rarediseases #populationhealth #AI #digitalhealth #individualizedmedicine #healthcareinnovation

Selection of October scientific NEWS. Exciting breakthrough in endometriosis research! 🔬A new study published in the journal Med has identified distinct stool metabolites in women with endometriosis, paving the way for non-invasive diagnosis and potential microbiota-based therapies. Key findings: • Unique bacteria-derived metabolite signature linked to endometriosis • Altered fecal metabolite profile similar to inflammatory bowel disease (IBD) • 4-hydroxyindole, a gut bacteria-derived metabolite, found to be lower in endometriosis patients • In vivo studies showed 4-hydroxyindole suppressed endometriosis-associated inflammation and pain. This groundbreaking research offers hope for faster diagnosis and new treatment options for the millions of women affected by endometriosis worldwide. Read the full paper: https://lnkd.in/ewQuBhZn #Endometriosis #WomensHealth #MedicalResearch #Microbiome #NonInvasiveDiagnostics

Our Expert Roundtable with Illumina, Cardiovascular Medicine in the Genomics Era, is coming up this week! Join Clint Founder Rajesh Dash MD PhD and our distinguished panel: Dr. Joshua Knowles, Nicholas Marston, MD, MPH, and Dr. Mauro Longoni on May 9th, 2024, at 4:30 p.m. EST for an insightful roundtable discussion. They will address current hurdles and explore tactics for fostering fair access and widespread adoption of genetic testing in clinical settings. 🔍 Key Topics We'll Explore: - How genetic testing can enhance patient management and outcomes in cardiology. - Factors contributing to the underutilization of genetic testing. - Variability in the recommendation of genetic tests across cardiology clinics. - Supporting healthcare providers in the confident use of genetic tests. Strategies to encourage wider adoption of genetic testing in cardiology. You don’t want to miss it. Register today! https://lnkd.in/gh77pEfc